Laurey Hanselman, DO
Family Medicine · Pigeon, MINPI 1033106372
Payments from drug & device makers
Across 340 payments — averaging $17.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$957
- Novo Nordisk$836
- Axsome Therapeutics, Inc.$541
- Amgen$506
- Otsuka America Pharmaceutical, Inc.$372
- Astellas Pharma US Inc$327
- plus $2K from 34 others
What the payments were for
- Food & beverage$5,85898%
- Education$1502%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 49 | $957 |
| Novo Nordisk | 67 | $836 |
| Axsome Therapeutics, Inc. | 25 | $541 |
| Amgen(2 entities) | 29 | $506 |
| Otsuka America Pharmaceutical, Inc. | 19 | $372 |
| Astellas Pharma US Inc | 14 | $327 |
| Johnson & Johnson | 16 | $290 |
| Pfizer | 17 | $284 |
| Merck | 12 | $197 |
| AstraZeneca | 10 | $156 |
| GSK | 7 | $116 |
| Lilly USA, LLC | 8 | $116 |
| Exact Sciences | 5 | $87 |
| Kowa Pharmaceuticals America, Inc. | 3 | $86 |
| Mylan Specialty L.p. | 4 | $85 |
| Edwards Lifesciences | 3 | $77 |
| Lundbeck LLC | 4 | $76 |
| Biohaven Pharmaceuticals, Inc. | 2 | $75 |
| Sumitomo Pharma America, Inc. | 2 | $71 |
| Avanir Pharmaceuticals, Inc. | 5 | $71 |
| Novartis | 4 | $69 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $64 |
| Bayer | 3 | $62 |
| Xeris Pharmaceuticals, Inc. | 3 | $55 |
| Boehringer Ingelheim | 3 | $41 |
| Verona Pharma, Inc. | 2 | $39 |
| Alkermes, Inc. | 2 | $39 |
| Sunovion Pharmaceuticals Inc. | 2 | $36 |
| Viatris Specialty LLC | 2 | $36 |
| Dexcom, Inc. | 2 | $34 |
| Inspire Medical Systems, Inc. | 1 | $29 |
| Krystal Biotech Inc | 2 | $29 |
| Amarin Pharma, Inc. | 2 | $24 |
| Vertex | 1 | $24 |
| Bioventus LLC | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| Abbott | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Athena Bioscience, LLC | 1 | $9 |
How this compares
$6,008 in reported general payments places this provider in the 90th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 212 | $232,986 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 197 | $190,452 |
| FarxigaDapagliflozin Propanediol | 183 | $187,239 |
| OzempicSemaglutide | 171 | $181,364 |
| JardianceEmpagliflozin | 157 | $156,650 |
| Humira(Cf)Adalimumab | 13 | $86,339 |
| TrulicityDulaglutide | 43 | $77,353 |
| XareltoRivaroxaban | 46 | $47,512 |
| MounjaroTirzepatide | 40 | $41,063 |
| RybelsusSemaglutide | 31 | $32,444 |
| MyrbetriqMirabegron | 29 | $24,875 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $21,973 |
| Spiriva HandihalerTiotropium Bromide | 30 | $21,775 |
| Tiotropium Bromide | 25 | $20,082 |
| Tresiba Flextouch U-100Insulin Degludec | 24 | $20,008 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $284 | $242,627232 claims |
| Novo NordiskOzempic, Rybelsus | $836 | $213,809202 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $116 | $200,507216 claims |
| AstraZenecaFarxiga, Brilinta | $156 | $194,895200 claims |
| Boehringer IngelheimJardiance | $41 | $156,650157 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $116 | $118,41683 claims |
| AbbVieHumira(Cf), Linzess | $957 | $101,99132 claims |
| Johnson & JohnsonXarelto, Invokana | $290 | $66,27866 claims |
| Astellas Pharma US IncMyrbetriq | $327 | $24,87529 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Pigeon
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
- Rhonda MejeurGrand Rapids$493K
- Steve LasaterSaint Johns$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.